Home Newsfeeds Benchmark Reiterates Buy on Harvard Bioscience, Maintains $4 Price Target

Benchmark Reiterates Buy on Harvard Bioscience, Maintains $4 Price Target

Benchmark analyst Kenneth Bruce reiterates Harvard Bioscience (NASDAQ:HBIO) with a Buy and maintains $4 price target.

byBenzinga Newsdesk

March 10, 2023

1 minute read

Benchmark analyst Kenneth Bruce reiterates Harvard Bioscience (NASDAQ:HBIO) with a Buy and maintains $4 price target.

Analyst Ratings

Analyst Ratings for OGE Energy

By Benzinga Insights

June 15, 8:04 AM

Within the last quarter, OGE Energy (NYSE:OGE) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…

OGE

Cannabis Scandal And Resignation Of Oregon Official, USCC’s New Leadership & More Executive Moves

By Jelena Martinovic

May 5, 8:45 AM

New Team Of Top Executives And Experts To Lead USCC Amid Possible Cannabis Policy Reform

AVTBF

Crypto ‘Dark Money’ Group Intensifies Lobbying Push In Anticipation Of 2024 Election

By Benzinga Neuro

January 9, 3:51 AM

Ahead of the 2024 elections, there is a notable increase in lobbying activities from the crypto industry. Key players in the sector, including the Cedar Innovation Foundation, are making strategic moves to influence lawmakers and policies in Washington.

$DOGE

Why This Longtime Comcast Bear Just Upgraded The Stock Down 30% This Year

By Priya Nigam

December 5, 12:13 PM

Shares of Comcast Corporation (NASDAQ: CMCSA) have lost close to 30% year to date. The adverse impact on Cable seems to have played out, according to Wells Fargo.

CMCSA

Benchmark Reiterates Buy on Harvard Bioscience, Maintains $4 Price Target

Related Posts

Analyst Ratings for OGE Energy

Cannabis Scandal And Resignation Of Oregon Official, USCC’s New Leadership & More Executive Moves

Crypto ‘Dark Money’ Group Intensifies Lobbying Push In Anticipation Of 2024 Election

Why This Longtime Comcast Bear Just Upgraded The Stock Down 30% This Year